H.C. Wainwright upgraded Sarepta Therapeutics (NASDAQ: SRPT) from Sell to Neutral with a new 12-month price target of $75. The
10 months ago
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged more than 27% in regular trading Tuesday following the company’s online statement about
